OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Review of Clinical Pharmacology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion	55
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis	53
A review of current and emerging therapies in breast cancer: implications for older adults	50
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed	40
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?	39
Clinical pharmacology of antiplatelet drugs	37
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions	35
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy	34
Reducing the risk of death – a possible outcome in COPD patients	34
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments	33
A simulation study to assess the influence of population pharmacokinetic model selection on Bayesian forecasting of vancomycin exposure in preterm neonates	32
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis	31
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome	28
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion	28
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review	27
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?	27
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies	25
Cannabidiol drug interaction considerations for prescribers and pharmacists	22
Medical management of pediatric chronic rhinosinusitis	22
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial	22
Amylin analogs for the treatment of obesity without diabetes: present and future	22
Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools	22